WuXia293Stable platform demonstrates high titer, human glycosylation and improved product quality by eliminating or significan...
Nanotein’s NanoSpark® reagents enhance cell activation and expansion in cell therapy manufacturing Exclusive global distribution agreement...
Axplora, a global leader in API small molecule manufacturing, today announced a significant investment at its Vizag site in India to expand production ca...
Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, announced Novasign and Repligen have entered ...
WuXi XDC Cayman Inc., a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate industry, announ...
As advanced modalities like mRNA and viral vectors reshape the biomanufacturing landscape, Cytiva is scaling innovation to meet evolving demands. In this e...
Phlow Corp., a leading American pharmaceutical contract development and manufacturing organization (CDMO), and Antheia, the pharmaceutical ingredient man...
Bio Usawa, a pioneering private biotechnology company committed to developing and manufacturing affordable, high‑quality monoclonal antibody therapies ...
Nelipak® Corporation (“Nelipak®”), a leading global provider of healthcare packaging solutions for medical device, diagnostic, pharma...
Bio Usawa Biotechnology Ltd. (Bio Usawa) and ServareGMP (Servare) announced a strategic partnership to establish advanced monoclonal antibody manufacturi...
Sygnature Discovery, a leading integrated drug discovery contract research organisation (CRO), today announces the completion of a major enhancemen...
Cytiva, a Danaher company and a leader in the life sciences industry, is expanding its ÄKTA portfolio with the addition of a system designed to opti...
Moderna provided an update on its two planned research and manufacturing facilities at Shonan Health Innovation Park (iPark) in Fujisawa, Kanagawa Prefectu...
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US Cornerstone of investment is...
© 2026 Biopharma Boardroom. All Rights Reserved.
